Close Menu

NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its first quarter revenues rose 84 percent year over year, thanks largely to a 103 percent increase in testing services revenues.

For the three months ended March 31, the molecular diagnostics company reported total revenues of $26.0 million, up from $14.1 million during the same period a year earlier, and beating the average Wall Street analyst estimate of $24.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.